Ads
related to: new nash drug
Search results
Results from the WOW.Com Content Network
(Reuters) -The U.S. FDA has approved Madrigal Pharmaceuticals' drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to get the nod for the condition ...
Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease. [1] [2] [3] [4]
(Reuters) -Madrigal Pharmaceuticals shares jumped as much as 23% on Friday after its oral drug became the first approved treatment for a fatty liver disease known as non-alcoholic steatohepatitis ...
NASH, which can progress to liver failure, affects 5% of the U.S. population, but development of a drug for the disease has seen numerous clinical failures, most recently by Intercept Pharmaceuticals.
Metabolic modulators tested in NASH include glucagon-like peptide-1 receptor agonists (GLP-1 agonists), GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) or glucagon co-agonists and thyromimetics. Some of these drugs may treat NAFLD by significantly reducing body weight. [165]
Resmetirom, sold under the brand name Rezdiffra, is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis. [1] It is a thyroid hormone receptor beta (NR1A2) agonist.
Non-alcoholic steatohepatitis, or NASH, is a metabolic disorder caused by a buildup of fat in the liver, leading to liver inflammation and damage. It belongs to a group of conditions called non ...
To encourage development and testing, the U.S. Food and Drug Administration (FDA) has issued fast track status. [ 2 ] Volixibat is an IBAT inhibitor, meaning that it blocks the function of the IBAT protein (ileal bile acid transporter), which is also called SLC10A2 (solute carrier family 10 member 2) or ASBT (apical sodium–bile acid transporter).
Ads
related to: new nash drug